NZ539083A - Orthopoxvirus virus vector, such as vaccina, in which the A46R protein from vaccinia, is not expressed or is expressed but is non-functional - Google Patents

Orthopoxvirus virus vector, such as vaccina, in which the A46R protein from vaccinia, is not expressed or is expressed but is non-functional

Info

Publication number
NZ539083A
NZ539083A NZ539083A NZ53908303A NZ539083A NZ 539083 A NZ539083 A NZ 539083A NZ 539083 A NZ539083 A NZ 539083A NZ 53908303 A NZ53908303 A NZ 53908303A NZ 539083 A NZ539083 A NZ 539083A
Authority
NZ
New Zealand
Prior art keywords
protein
vector
tlr
myd88
orthopoxvirus
Prior art date
Application number
NZ539083A
Other languages
English (en)
Inventor
Luke Anthony John O'neill
Andrew Graham Bowie
Julianne Stack
Geoffrey Lilley Smith
Ismar Rocha Haga
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Publication of NZ539083A publication Critical patent/NZ539083A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ539083A 2002-10-01 2003-09-29 Orthopoxvirus virus vector, such as vaccina, in which the A46R protein from vaccinia, is not expressed or is expressed but is non-functional NZ539083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20020790 2002-10-01
PCT/IE2003/000131 WO2004031225A1 (fr) 2002-10-01 2003-09-29 Vecteurs d'orthopoxvirus, genes et produits associes

Publications (1)

Publication Number Publication Date
NZ539083A true NZ539083A (en) 2007-06-29

Family

ID=32051172

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ539083A NZ539083A (en) 2002-10-01 2003-09-29 Orthopoxvirus virus vector, such as vaccina, in which the A46R protein from vaccinia, is not expressed or is expressed but is non-functional

Country Status (5)

Country Link
EP (1) EP1546192A1 (fr)
AU (1) AU2003273512A1 (fr)
CA (1) CA2499871A1 (fr)
NZ (1) NZ539083A (fr)
WO (1) WO2004031225A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755670A4 (fr) * 2004-05-28 2008-07-02 Cedars Sinai Medical Center Methodes pour traiter des maladies vasculaires
CA2483732A1 (fr) * 2004-09-29 2006-03-29 Ronan Le Goffic Recepteur 3 de type toll, sa molecule associee du type trif (trifluoromethanesulfonate) et utilisations connexes
GB0605761D0 (en) * 2006-03-22 2006-05-03 Imp Innovations Ltd Anti-inflammatory proteins and improved vaccines
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
WO2010033294A1 (fr) 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Md-2 humaine sous sa forme courte utilisée comme régulateur négatif de la signalisation par le récepteur de type toll-4
US8722052B2 (en) 2008-11-17 2014-05-13 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Vaccinia virus protein A46 peptide and use thereof

Also Published As

Publication number Publication date
AU2003273512A1 (en) 2004-04-23
CA2499871A1 (fr) 2004-04-15
WO2004031225A1 (fr) 2004-04-15
EP1546192A1 (fr) 2005-06-29

Similar Documents

Publication Publication Date Title
Volz et al. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development
Jacobs et al. Vaccinia virus vaccines: past, present and future
Clark et al. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
Kerr et al. Immune responses to myxoma virus
Lüschow et al. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene
Fang et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain
JP5988463B2 (ja) Ｍｖａによる病原体からの即時保護
Aurelian et al. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
Dai et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes
Meng et al. Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L
US20050244430A1 (en) Orthopoxvirus vectors, genes and products thereof
Jentarra et al. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination
NZ539083A (en) Orthopoxvirus virus vector, such as vaccina, in which the A46R protein from vaccinia, is not expressed or is expressed but is non-functional
Smith Genus Orthopoxvirus: vaccinia virus
US7431929B2 (en) Use of vaccinia virus deleted for the E3L gene as a vaccine vector
WO2004087047A2 (fr) Mutants de virus de la vaccine aptes a la replication
US20090143289A1 (en) Orthopoxvirus vectors, genes and products thereof
Lynch et al. Modified vaccinia virus Ankara can activate NF-κB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication
IE20030710A1 (en) Orthopoxvirus vectors, genes and products thereof
IE20030641A1 (en) Orthopoxvirus vectors, genes and products thereof
Barrett et al. Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits
WO2013011179A2 (fr) Vecteurs recombinants à base du virus ankara modifié (mva) avec délétion dans le gène c6l, utilisés comme vaccins contre le vih/sida et d'autres maladies
Martin Examination of the role of early viral protein expression in MVA-induced NF-κB activation
Sonstein et al. TLR3 Increases Disease Morbidity and

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)